Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Celecoxib safe for short-term use in patients with cirrhosis

23.02.2005


Naproxen harms renal function after short-term use in cirrhotic patients



Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver, according to a recent study that compared the effects of celecoxib, naproxen, and a placebo on cirrhotic patients in a double-blind randomized controlled study. The findings are published in the March 2005 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD). Published by John Wiley & Sons, Inc., the journal is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/hepatology.

Previous studies in experimental cirrhosis have shown that selective COX-2 inhibitors, such as celecoxib, do not affect renal function. By contrast, nonsteroidal anti-inflammatory drugs, including naproxen, have long been associated with acute renal failure in cirrhotic patients. To further investigate these findings, researchers, led by Joan Clària of Barcelona’s Hospital Clinic, sought to compare the effects of celecoxib, naproxen and a placebo on cirrhotic patients.


They recruited 28 patients who had cirrhosis and ascites and increased activity of the renin-angiotensin system. Each one was randomly assigned to a short-term course (5 doses over 60 hours) of celecoxib, naproxen or a placebo. Results from ten of the participants were not considered in the analysis due to the discovery of hepatorenal syndrome, or lack of stable serum concentrations of clearance substances needed to calculate glomerular filtration rate (GFR) and renal plasma flow (RPF.) For the remaining patients, the researchers measured and monitored platelet and renal function, as well as the diuretic and natriuretic responses to furosemide.

Celecoxib, like the placebo, did not inhibit platelet aggregation or thromboxane B2 synthesis, while naproxen did. Celecoxib also did not affect renal function, according to RPF, GFR and serum creatinine values, while naproxen reduced both RPF and GFR and increased serum creatinine levels. Neither celecoxib nor the placebo affected the diuretic or natriuretic effects of furosemide or the urinary excretion of prostaglandins. Naproxen significantly reduced both the diuretic and natriuretic responses to furosemide. Interestingly, both celecoxib and naproxen significantly reduced plasma renin activity after furosemide administration.

"These results suggest that selective COX-2 inhibitors may be safer than nonselective nonsteroidal anti-inflammatory drugs in these patients," the authors report. "Further studies using COX-2 inhibitors for a longer period of time are required to confirm this contention."

The researchers used a short-term administration of the drugs in question to prevent any significant impairment in kidney function. As a result, the study does not offer information about the safety of these drugs when administered for long-term therapeutic purposes.

"In summary," say the authors, "the current study indicates that naproxen, but not celecoxib, administered during a short period of time, adversely affects renal function and the renal response to furosemide in cirrhotic patients with ascites and increased activity of the renin-angiotensin system."

David Greenberg | EurekAlert!
Further information:
http://www.interscience.wiley.com/journal/hepatology

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

17.01.2017 | Materials Sciences

Smart homes will “LISTEN” to your voice

17.01.2017 | Architecture and Construction

VideoLinks
B2B-VideoLinks
More VideoLinks >>>